Treats major depressive disorder (MDD). ANDA 211323, held by Cadila Pharmaceuticals. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 211323 (Venlafaxine Hydrochloride), held by Cadila Pharmaceuticals, was first approved by FDA on Aug 29, 2019, with 2 approved supplements and 0 published complete response letters.
Venlafaxine extended-release tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) Social Anxiety Disorder (SAD) 1.1 Major Depressive Disorder Venlafaxine extended-release tablets are indicated for the treatment of major depressive disorder (MDD). Efficacy of venlafaxine in MDD was shown in both short-term trials and a longer-term trial in MDD.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 29, 2019 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 75MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 150MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 225MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Feb 1, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 21, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 29, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters